Efficacy and immunological changes of sublingual immunotherapy in pediatric allergic rhinitis.
Allergic
Cytokines
Efficacy
Rhinitis
Sublingual immunotherapy
Treatment outcome
Journal
The World Allergy Organization journal
ISSN: 1939-4551
Titre abrégé: World Allergy Organ J
Pays: United States
ID NLM: 101481283
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
15
11
2022
revised:
11
05
2023
accepted:
07
07
2023
medline:
31
7
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
epublish
Résumé
Allergen-specific immunotherapy, including subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), improves the disease progression of allergic rhinitis (AR). SCIT and SLIT exhibit similar efficacy, but SLIT has less systemic reactions. However, few studies have investigated the underlying mechanisms of SLIT treatment. In this study, we explored the efficacy of SLIT under different treatment durations and immunological changes. This retrospective study was conducted from August 2017 to August 2022 in our hospital. A total of 314 children who underwent SLIT were divided into the following groups based on their treatment duration: the 1 year group (6 months-1 year), the 2 years group (1-2 years), and the 3 years group (2-3 years). The treatment efficacy was confirmed using a combined symptom and medication score (SMS). Multiple serum cytokines were measured using Luminex. Various immune cells in PBMCs were determined using flow cytometry. The total nasal symptom score (TNSS), rescue medication score (RMS), and SMS of the 3 years group was significantly different from those of the 1 years and 2 years groups. At the end of the 2 years following cessation of SLIT, the following results were observed in the 3 years group: 1) the TNSS, RMS, and SMS had significantly improved, 2) the serum IL-10, TGF-beta, and IL-35 levels had increased significantly, and 3) the percentages of regulatory T cell, regulatory B cell, and follicular regulatory T cell increased significantly. Our results suggest that 3 years of SLIT is necessary for long-term effects and continued immunological changes.
Sections du résumé
Background
UNASSIGNED
Allergen-specific immunotherapy, including subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), improves the disease progression of allergic rhinitis (AR). SCIT and SLIT exhibit similar efficacy, but SLIT has less systemic reactions. However, few studies have investigated the underlying mechanisms of SLIT treatment. In this study, we explored the efficacy of SLIT under different treatment durations and immunological changes.
Methods
UNASSIGNED
This retrospective study was conducted from August 2017 to August 2022 in our hospital. A total of 314 children who underwent SLIT were divided into the following groups based on their treatment duration: the 1 year group (6 months-1 year), the 2 years group (1-2 years), and the 3 years group (2-3 years). The treatment efficacy was confirmed using a combined symptom and medication score (SMS). Multiple serum cytokines were measured using Luminex. Various immune cells in PBMCs were determined using flow cytometry.
Results
UNASSIGNED
The total nasal symptom score (TNSS), rescue medication score (RMS), and SMS of the 3 years group was significantly different from those of the 1 years and 2 years groups. At the end of the 2 years following cessation of SLIT, the following results were observed in the 3 years group: 1) the TNSS, RMS, and SMS had significantly improved, 2) the serum IL-10, TGF-beta, and IL-35 levels had increased significantly, and 3) the percentages of regulatory T cell, regulatory B cell, and follicular regulatory T cell increased significantly.
Conclusion
UNASSIGNED
Our results suggest that 3 years of SLIT is necessary for long-term effects and continued immunological changes.
Identifiants
pubmed: 37520614
doi: 10.1016/j.waojou.2023.100803
pii: S1939-4551(23)00063-7
pmc: PMC10382672
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100803Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no relevant conflicts of interest.
Références
Inflamm Res. 2021 May;70(5):581-589
pubmed: 33837438
J Allergy Clin Immunol. 2019 Jul;144(1):118-128
pubmed: 30796979
Allergol Int. 2020 Oct;69(4):549-560
pubmed: 32900655
Allergy. 2005 Jan;60(1):4-12
pubmed: 15575924
J Allergy Clin Immunol. 2010 Nov;126(5):969-75
pubmed: 20934206
J Allergy Clin Immunol. 2009 May;123(5):1103-10, 1110.e1-4
pubmed: 19356792
Int Forum Allergy Rhinol. 2016 Jan;6(1):82-7
pubmed: 26575696
Immunity. 2021 Feb 9;54(2):291-307.e7
pubmed: 33450188
Allergy. 2018 Sep;73(9):1823-1832
pubmed: 29517806
Allergy Asthma Immunol Res. 2015 Mar;7(2):99-100
pubmed: 25729615
World Allergy Organ J. 2022 Sep 07;15(9):100691
pubmed: 36119654
Pediatr Allergy Immunol. 2015 Feb;26(1):34-41
pubmed: 25378059
Allergy. 2016 Aug;71(8):1170-80
pubmed: 26948849
Clin Exp Allergy. 2016 Sep;46(9):1139-51
pubmed: 27434218
Clin Exp Allergy. 2013 Oct;43(10):1171-9
pubmed: 24074335
Curr Opin Allergy Clin Immunol. 2019 Feb;19(1):12-17
pubmed: 30507716
J Allergy Clin Immunol. 2017 Oct;140(4):950-958
pubmed: 28602936
Allergy. 2006;61 Suppl 82:1-20
pubmed: 16930249
J Allergy Clin Immunol. 2022 May;149(5):1691-1701.e9
pubmed: 35093485
Allergol Int. 2013 Dec;62(4):403-13
pubmed: 24280670
Immunotherapy. 2019 Apr;11(6):473-482
pubmed: 30860439
Curr Opin Allergy Clin Immunol. 2018 Dec;18(6):495-501
pubmed: 30124489
Curr Treat Options Allergy. 2018;5(3):275-290
pubmed: 30221122
J Allergy Clin Immunol. 2020 Oct;146(4):721-767
pubmed: 32707227
J Allergy Clin Immunol. 2018 May;141(5):1750-1760.e1
pubmed: 29128670
Open Med (Wars). 2021 May 21;16(1):826-832
pubmed: 34056115
Nat Med. 2011 Jul 24;17(8):975-82
pubmed: 21785433
Int Immunopharmacol. 2022 Nov;112:109187
pubmed: 36037652